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Abstract: Skin cancer is among the most common cancer types accompanied by rapidly increasing
incidence rates, thus making the development of more efficient therapeutic approaches a necessity.
Recent studies have revealed the potential role of decosahexaenoic acid ester of phloridzin (PZDHA)
in suppressing proliferation of liver, breast, and blood cancer cell lines. In the present study,
we investigated the cytotoxic potential of PZDHA in an in vitro model of skin cancer consisting
of melanoma (A375), epidermoid carcinoma (A431), and non-tumorigenic (HaCaT) cell lines.
Decosahexaenoic acid ester of phloridzin led to increased cytotoxicity in all cell lines as revealed by
cell viability assays. However, growth inhibition and induction of both apoptosis and necrosis was
more evident in melanoma (A375) and epidermoid carcinoma (A431) cells, whereas non-tumorigenic
keratinocytes (HaCaT) appeared to be more resistant as detected by flow cytometry. More specifically,
PZDHA-induced cell cycle growth arrest at the G2/M phase in A375 and A431 cells in contrast to
HaCaT cells, which were growth arrested at the G0/G1 phase. Elevated intracellular generation of
reactive oxygen species ROS was detected in all cell lines. Overall, our findings support the potential
of PZDHA as a novel therapeutic means against human skin cancer.
Keywords: phloridzin; docosahexaenoic acid; flavonoids; skin cancer; melanoma; epidermoid
carcinoma; apoptosis; necrosis; cell cycle; oxidative stress; reactive oxygen species
1. Introduction
Skin cancer constitutes one of the most common types of cancer in the Caucasian population, with
its incidence rates continuously increasing worldwide [1–5]. It is categorized into melanoma (MM)
and non-melanoma skin carcinomas (NMSCs), with MM constituting one of the most aggressive and
lethal solid tumor types. A large number of reports have associated exposure to UV irradiation
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with an increased frequency of mutations responsible for MM’s occurrence [6,7]. On the other
hand, NMSC involves basal (BCC) and squamous (SCC) cell carcinomas, both of which are different
types of keratinocyte carcinomas and are the most common type of malignancies in Caucasians.
Incidence of NMSC has also been linkedwith increased Ultraviolet Radiation (UVR) exposure; however,
its metastatic potential and mortality rates remain relatively low compared to MM [1,2,8].
Flavonoids represent a major group of polyphenols whose beneficial effects have been the subject
of numerous studies exhibiting their anti-microbial, anti-oxidant, anti-inflammatory, anti-cancer, and
anti-mutagenic properties [9,10]. One of the major flavonoids found in apples is phloridzin (phlorizin
or phloretin 20-O-glucoside) which, in addition to several other hydrochalcone compounds, has been
demonstrated to possess anti-cancer properties against lung, liver, and colon cancer cell lines [11–13].
In addition, cryptocaryone as well as other dihydrochalcone compounds were shown to trigger tumor
necrosis factor alpha-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human prostate
cancer cells [14,15]. The anti-proliferative effects of chalcone derivatives together with their ability
to inhibit their invasiveness have been also documented in breast cancer cells [16]. A recent report
described the acylation of flavonoid glucosides (with long chain fatty acids) and their esterification by
Lipase B to result in the synthesis of fatty acid esters of phloridzin capable of inducing cytotoxicity
in liver, breast, and blood cancer cells together with induction of cell cycle arrest, suppression of
DNA topoisomerase IIa, and activation of apoptosis [17,18]. Interestingly, decosahexaenoic acid ester
of phloridzin (PZDHA) was found to be the most promising, amongst the other ester compounds,
thus its effects were further explored in subsequent studies. More specifically, PZDHA was shown
to possess anti-inflammatory properties in THP-1 differentiated macrophages following exposure to
lipopolysaccharide (LPS) [19]. Moreover, it was demonstrated that PZDHA selectively induced the
killing of breast cancer cell lines whereas non-malignant breast cells remained unaffected. Additional
experiments with breast cancer cell lines and breast cancer xenograft models indicated induction of
cell cycle growth arrest (at G2/M phase), activation of apoptosis, and overall suppression of tumor
growth [20].
However, the effects of PZDHA on experimental models of skin cancer have not yet been
investigated. To this end, our in vitro model of skin cancer consisted of two different skin cancer types,
namely A375 (MM) andA431 (NMSC) cell lines as well as a non-tumorigenic immortalized keratinocyte
(HaCaT) cell line. The latter was used in the context of providing a control, a non-malignant cell
type which predominantly exists in the epidermis in addition to the basal layer of the skin (basal
keratinocytes) [21]. Our hypothesis is that the cancer skin cell lines would be selectively more sensitive
to cytotoxicity-induced by PZDHA when compared to the non-tumorigenic cell line. We would expect
such observations to be recorded as lower concentration of the compound that gives half-maximal
response (EC50) values and/or higher levels of other cytotoxicity endpoints such as those of apoptosis,
necrosis, oxidative stress, and cell cycle growth arrest. In support of our hypothesis, previous
studies have demonstrated that exposure to PZDHA is cytotoxic in liver and breast cancer cells
while non-malignant hepatocytes and mammary cells remained unaffected [18,20]. Therefore, in the
present study we aimed to examine the potential role of PZDHA in an in vitro model of skin cancer
by assessing its potential to act as a selective cytotoxic agent in inducing cell cycle growth arrest,
generation of oxidative stress, and activation of cancer cell death. Such approaches are justified in the
context of developing targeted therapeutic approaches aiming to utilize compounds/agents with the
capacity to selectively induce cytotoxicity in cancer cells while non-tumorigenic cells are either not
affected or more resistant.
2. Materials and Methods
2.1. Chemicals, Reagents, and Test Compound
Dulbecco’s Modified Eagle’s Medium (DMEM), phosphate buffer saline (PBS), fetal bovine serum
(FBS), trypsin, penicillin/streptomycin, and L-glutamine were obtained from Labtech International Ltd.
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(Sussex, UK). The CellEvent Caspase 3/7 Green flow cytometry assay kit, FxCycle PI/RNase staining
solution, and DAPI dye were supplied by Thermo Scientific (Waltham, MA, USA). Dihydrorhodamine
123 (DHR 123) and resazurin sodium salt were purchased from Sigma–Aldrich (St. Louis, MO, USA).
All chemicals were of analytical grade and obtained from Invitrogen (Carlsbad, CA, USA), Applichem
(Darmstadt, Germany), and Sigma–Aldrich. Synthesis of PZDHA based according to Ziaullah et al. [17].
Stock solutions (100 mM) were prepared in DMSO and stored at  20  C.
2.2. Cell Lines
The human malignant melanoma (A375) and epidermoid carcinoma (A431) cell lines were
purchased from Sigma–Aldrich (St. Louis, MO, USA). The human immortalized keratinocyte
(HaCaT) cell line was kindly provided by Dr. Broby (Dermal Toxicology and Effects Group; Public
Health England, UK). All cell lines were maintained in DMEM medium with high glucose content,
supplemented with 10% FBS, 2 mM L-glutamine, and 1% pen/strep (100 U/mL penicillin, 100 µg/mL
streptomycin). Cells were cultured in a humidified atmosphere at 37  C and 5% CO2, grown as
monolayers and sub-cultured at 80–90% confluency. All cell lines were cultured for 15–20 passages
before new stocks were utilized. Cell culture media and reagents were purchased from Labtech (East
Sussex, UK) whereas all cell culture plasticware were obtained from Corning (Corning, NY, USA).
2.3. Cell Viability Assay
The Alamar-blue assay was utilized where resazurin was converted to resorufin in metabolically
active cells with the resulting elevation in absorbance being proportional to the levels of viable cells.
Briefly, A375, A431, and HaCaT cells were seeded into 96-well plates in 100 µL/well and incubated
overnight prior to exposure to PZDHA. Cell density of A375 was 8000 and 4000 cells/well and for A431
and HaCaT 10,000 and 5000 cells/well for 24 and 48 h, respectively. On the following day, cells were
exposed to a range of concentrations (1, 10, 25, 50, 75, and 100 µM) over different incubation periods.
For control conditions, cells were incubated with complete medium only or medium containing 0.1%
DMSO (vehicle). At the indicated time points, fresh medium (containing 0.1 mg/mL resazurin) was
added into each well and incubated for 2–4 h (depending on the type of cancer cell line), at 37  C.
The plates were then centrifuged, and absorbance was recorded at 570 nm and 600 nm (reference
wavelength) using a Spark multimode plate reader (Tecan, Switzerland). The levels of cell viability
were estimated and expressed as percentage of control cells.
2.4. Determination of Apoptosis by Flow Cytometry
The CellEvent Caspase 3/7 Green flow cytometry assay kit was utilized for the detection of
apoptosis according to the manufacturer’s instructions. Briefly, cells were plated into 100 mm dishes
and allowed to adhere overnight. Cell density of A375 was 1.4 ⇥ 106 and 0.7 ⇥ 106 cells per dish and
for A431 and HaCaT 1.5 ⇥ 106 and 0.8 ⇥ 106 cells per dish for 24 and 48 h, respectively. The next
day, cells were exposed to PZDHA for 24 or 48 h. Next, cells were harvested, washed twice with PBS
and a single cell suspension of 106 cells/mL was prepared. Then, 0.5 µL of CellEvent Caspase 3/7
Green detection reagent was added into 0.5 mL of each cell suspension and samples were incubated
at 37  C for 30 min. Five min prior to the end of the incubation period, 1 µM of DAPI was added.
Data acquisition and analysis of 20,000 events, for each sample, was performed using a FACS Canto
II (BD Biosciences, San Jose, CA, USA) flow cytometer. Caspase-3/7-positive cells were identified as
apoptotic and DAPI-positive cells as necrotic.
2.5. Morphological Observation under Inverted Phase Contrast Microscope
A375, A431, and HaCaT cells were seeded in 100 mm dishes and exposed to either vehicle (0.1%
DMSO) or 70 µM PZDHA for 24 and 48 h. The density of A375 cells was 1.4 ⇥ 106 and 0.7 ⇥ 106 per
dish while for A431 and HaCaT cells was 1.5 ⇥ 106 and 0.8 ⇥ 106 per dish for 24 and 48 h, respectively.
At the indicated time points, the morphology of cells was observed by an inverted phase contrast
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microscope (ZOE fluorescent cell imager, Bio-rad, Hercules, CA, USA) and images were captured at
20⇥magnification.
2.6. Cell Cycle Analysis by Flow Cytometry
The FxCycle PI/RNase staining solution was used according to the manufacturer’s instructions.
Following exposure to PZDHA, cells were harvested and washed twice with PBS. The density of A375
cells was 1.4 ⇥ 106 and 0.7 ⇥ 106 per dish while for A431 and HaCaT cells was 1.5 ⇥ 106 and 0.8 ⇥ 106
per dish for 24 and 48 h, respectively. Approximately 0.5 ⇥ 106 cells were fixed in cold 70% ethanol,
for 1 h or longer, at 4  C until further processed. Cells were then washed twice with PBS to remove
ethanol and finally suspended in FxCycle PI/RNase staining solution for 30 min at room temperature
(RT) in the dark. Data acquisition and analysis of 10,000 events, for each sample, was performed using
a FACS Canto II (BD Biosciences) flow cytometer.
2.7. Measurement of Intracellular ROS
After cells were exposed to PZDHA, they were harvested and washed twice with PBS. The density
of A375 cells was 1.4 ⇥ 106 and 0.7 ⇥ 106 per dish while for A431 and HaCaT cells was 1.5 ⇥ 106
and 0.8 ⇥ 106 per dish for 24 and 48 h, respectively. A single cell suspension of 106 cells/mL was
prepared and dihydrorhodamine 123 (DHR 123; 10 µM) was added and incubated for 5 min at 37  C.
One (1) µM of DAPI was also added to each sample and incubated for 5 min for staining of dead cells.
Data acquisition and analysis of 10,000 events, for each sample, was performed using a FACS Canto II
(BD Biosciences) flow cytometer. Finally, DAPI positive cells were excluded from further analysis of
the results.
2.8. Statistical Analysis
All data were expressed as mean values ± SD and comparisons were made between control and
PZDHA-exposed groups. Statistical analyses were performed by one-way ANOVA with Tukey’s test
for multiple comparisons after using the SPSS v.22 software. Statistical significance was set at p < 0.05.
Finally, EC50 values were calculated utilizing the Sigma Plot v12.5 software.
3. Results
Cytotoxicity of PZDHA was investigated in an in vitro model of skin cancer consisting of human
malignant melanoma (A375), epidermoid carcinoma (A431), and immortalized non-tumorigenic
keratinocyte (HaCaT) cell lines. Initial experiments involved the determination of viability curves in
all three cell lines following exposure to various concentrations of PZDHA over different incubation
periods. According to our results, PZDHA induced cytotoxicity in a dose- and time-dependent manner
in all three cell lines and to a similar extent (Figure 1A). Concentration of the compound that gives
half-maximal response EC50 values were determined to be 56.2, 57.3, and 60.9 µM, while they were
reduced to 42.1, 44.3, and 44.5 µM after 24 h and 48 h of incubation with PZDHA in A375, A431,
and HaCaT cells, respectively (Figure 1B).
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by utilizing the Alamar-blue assay. Data are expressed as percentage of control cells and are presented 
as means ± SD (n = 5). Data are representative of two independent experiments. Finally, (c) represents 
statistical significance set at p < 0.001. 
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accompanied with increased apoptotic and necrotic levels, respectively (Figure 2A,D). In comparison, 
A431 cells were more sensitive as there was a profound decrease in cell viability levels while both 
apoptosis and necrosis increased respectively, at 24 h of exposure, (Figure 2B,E) followed by an even 
more profound effect after 48 h of exposure (Figure 2B,E). Interestingly, HaCaT cells were found to 
be more resistant compared to both cancer cell lines, throughout the entire exposure period (Figure 
2C,F). At the same time, there was an increase of apoptosis and necrosis at both time courses (Figure 
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A431 cells being more sensitive and HaCaT more resistant when compared to A375 cells. 
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more sensitive as there was a profound decrease in cell viability levels while both apoptosis and
necrosis increased respectively, at 24 h of exposure, (Figure 2B,E) followed by an even more profound
effect after 48 h of exposure (Figure 2B,E). Interestingly, HaCaT cells were found to be more resistant
compared to both cancer cell lines, throughout the entire expos re period (Figure 2C,F). At the same
time, there was an increase of apoptosis and necrosis at b th time courses (Figure 2C,F). Overall, it was
apparent th t PZDHA trigg red cell death cascades, in all three cell lines, with A431 cells bei g more
sensitive and HaCaT more resist t when co pared to A375 cells.
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70 μM PZDHA for 24 and 48 h and subsequently incubated with DEVD-substrate and DAPI for the 
detection of apoptotic and dead cells respectively. Quantification of live, apoptotic, and dead 
subpopulations in A375 (D), A431 (E), and HaCaT (F) cells treated with 70 μM PZDHA for 24 and 48 
h. Data are presented as means ± SD (n = 3) and are representative of two independent experiments. 
Finally, (a) represents statistical significance set at p < 0.05, and (c) at p < 0.001. 
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In addition, we observed morphological alterations in all cell lines following exposure to 70 µM
PZDHA for 24 and 48 h by utilizing inverted phase contrast microscopy. Such exposure to PZDHA
had a significant effect on the confluency levels of all cell lines, however HaCaT appeared to be less
affected compared to A375 and A431 cells (Figure 3). Also, there appeared to be PZDHA-induced
alterations on the shape and morphology of all cell lines as cellular membrane structure appeared to
be distorted causing cells to shrink and consequently detach from the plates.Antioxidants 2018, 7, x FOR PEER REVIEW  7 of 12 
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course (Figure 4A,B). Surprisingly, HaCaT cells exhibited a growth arrest in G0/G1 phase under both 
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A431 and HaCaT cells it was found to be equal to 1.5-fold at 24 h and dropping to control levels at 48 
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Figure 3. Morphological changes of cells upon exposure to PZDHA. Representative images of A375,
A431, and HaC T cells treat d either with vehicle (0.1% DMSO) or PZDHA (70 µM) for 24 and 48 h.
Images were recorded by utilizing the ZOE fluorescent cell imager at 20⇥magnification.
Moreover, exposure of A375 cells to PZDHA, over 24 h, led to very minor changes in the contents
of G2/M and S phases, while at 48 h there were more substantial changes occurred including a major
shift to the G2/M phase (Figure 4A,B). Similarly, PZDHA induced G2/M and S phases growth arrest
in A431 cells accompanied by a marked increase in sub-G1 population throughout the entire time
course (Figure 4A,B). Surprisingly, HaCaT cells exhibited a growth arrest in G0/G1 phase under both
exposure periods (Figure 4A,B). Overall, our data suggest a different pattern of cell cycle distribution
between tumorigenic (A375 and A431) and non-tumorigenic (HaCaT) cells.
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Histograms show cell cycle distribution of A375, A431, and HaCaT cells in response to 70 μM PZDHA 
exposure for 24 and 48 h (A). Quantification of cell subpopulations under different cell cycle phases 
(e.g., sub-G1, G0/G1, S, G2/M) (B). Data are presented as means ± SD (n = 3) and are representative of 
two independent experiments. Finally, (a) represents statistical significance set at p < 0.05, (b) at p < 
0.01, and (c) at p < 0.001. 
Figure 4. The effect of PZDHA on cell cycle distribution in an in vitro model of skin cancer. Histograms
show cell cycle distribution of A375, A431, and HaCaT cells in response to 70 µM PZDHA exposure for
24 and 48 h (A). Quantification of cell subpopulations under different cell cycle phases (e.g., sub-G1,
G0/G1, S, G2/M) (B). Data are presented as means ± SD (n = 3) and are representative of two
independent experiments. Finally, (a) represents statistical significance set at p < 0.05, (b) at p < 0.01,
and (c) at p < 0.001.
Finally, we evaluated generation of ROS as a response to PZDHA exposure and our data
demonstrated that there was induction of oxidative stress in all three cell lines. However,
ROS generation in A375 cells was more profound (at 48 h) as indicated by a 1.7-fold change, whereas
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in A431 and HaCaT cells it was found to be equal to 1.5-fold at 24 h and dropping to control levels at
48 h (Figure 5A–C).Antioxidants 2018, 7, x FOR PEER REVIEW  9 of 12 
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particular cancer cell type used in each case since other studies have shown the existence of a G0/G1 
Figure 5. The effect of PZDHA on generation of oxidative stress in an in vitro model of skin cancer.
Quantification of ROS generation in response to 70 µM PZDHA over 24 and 48 h of exposure in A375
(A), A431) (B), and HaCaT (C) cells. Data are expressed as fold change compared to control cells and
presented as means ± SD (n = 3). Data are representative of two independent experiments. Finally,
(c) represents statistical significance set at p < 0.001.
4. Discussion
According to our results, PZDHA was shown to be cytotoxic in all three cell lines. However,
HaCaT ells were shown to be more resistant, at higher con entrations of the compound, compar d to
both cancer cell lines (Figure 1A). In add tio , EC50 values were equal to approxi ately 60 and 40 µM
f r 24 and 48 h, resp ctively in all cell lines (Figure 1B). These observati ns a e in agreement with
the cu rent literature as this derivative of phloridzin has been previously shown to exe t cytotoxicity
against liver and bre t carcinomas while n t affecting non-malignant cell lines of the same tissue
type. In addition, the observed EC50 values followed the same range of co centrations as in our
experimental model [18,20]. In order to investigate further into th anti-pr liferative effects of PZDHA,
in our model, we looked into the mode f cell death activation. Our findings confirmed triggering
of both apoptosis and necrosis, in all three cell lines, following treatment with 70 µM PZDHA but to
a different extent de ending o the ell type (Figure 2A–F). More specifically, A431 cells exhibited
higher levels f apoptosis and necrosis compared to A375 cells. In comparis n, HaCaT cells were
more resistant amongst a l three cell lines (Figu e 2A–F). The participation of the apoptotic cascade
via caspase-3/7 act vation has been also shown other in vitro cancer models, including breast, liver,
and blood, in response to PZDHA tre tm nt [18,20,22]. Numerous other eports have documente the
ability of a wide range of flavonoids to stimulate apoptosis in various cancer types, thus indicating
their chemo-pr ventive properties [23,24]. On another note, i is worth mentioning that PZDHA
has been shown to inhibit tyrosinase compared to its parental compou d (phloridzin) [17]. To this
end, melanocytes ar capable of producing mel nin (res onsible for protecting cells by absorbing UV
radiati n) while L-tyrosine positively regulates melano enesis a d augments melanocytes’ metastatic
potential [25,26]. Elevated levels of melanin, in metastatic mel noma cells, have been linked to the
progression of the disease while also having a negative impact on the effec iveness of radiation
therapy [27]. Several flavonoids have been stu ied for their ability to act either as positive or negativ
regulators in mel nogenesis; however, th exact mechan sms of how they ex rt their anti-proliferative
and anti-metastatic properties are not fully elucidated [28]. Nevertheless, there is encouraging evidence
on th b neficial effects of several flavonoids by their conjunction with nanoparticles for their targeted
d livery in in vitro and i vivo models of melanoma [29–32]. Henc , PZDHA could potent ally ac as a
new and promising ap roach in melanoma treatment. Moreover, when assessing cell cycle distribution
after exposure to PZ a quite disti ct pattern was evident characterized by a G2/M growth arrest
ph se in A375 and A431 cells in contrast to a G0/G1 growth rrest pha e in HaCaT cells (Figure 4A,B).
Evide ce from a numbe of oth r studies has indicated tha different flavonoi s are associated with a
Antioxidants 2018, 7, 188 10 of 12
G2/M growth arrest phase in various cancer cell lines [33,34]. However, such effect depends on the
action of the specific flavonoid and the particular cancer cell type used in each case since other studies
have shown the existence of a G0/G1 growth arrest phase as well [35,36]. In particular, exposure of
hepatoma (HepG2) cells to PZDHA was shown to induce growth arrest in G0/G1 phase [18], whereas
PZDHA exposure to breast carcinoma (MDA-MB-231) cells caused growth arrest in G2/M phase [20].
In addition, the fact that both A375 and A431 cells have a wild-type p53 status [37,38] while HaCaT
cells have a p53-mutated one [39] suggests that such observed differences in cell cycle distribution
could, perhaps, be attributed to p53 status. Finally, although PZDHA-induced stimulation of oxidative
stress was evident in all three cell lines, there was a differential response in ROS production based on
the cell type itself and in the context of being either a melanoma (A375) or a non-melanoma (A431) or
a keratinocyte (HaCaT) one (Figure 5A–C). In addition, induction of oxidative stress can be linked to
alterations in cell cycle distribution [40] as well as activation of cell death [41]. Moreover, although
the antioxidant properties of PZDHA have been previously documented [17], it is widely known that
high concentrations of antioxidants can result in the induction of oxidative stress as a consequence of
pro-oxidant effects [42].
5. Conclusions
Collectively, in the present study we have provided evidence that a novel polyphenol fatty acid
ester derivative, PZDHA, is cytotoxic against melanoma (A375) and non-melanoma skin cancer (A431)
cells, while non-tumorigenic keratinocyte (HaCaT) cells appeared to be more resistant. Furthermore,
we demonstrated the occurrence of such a distinct cytotoxicity profile in the context of activated
apoptosis and necrosis, induced alterations in cell cycle distribution, as well as increased generation of
oxidative stress. In conclusion, our study provides preliminary evidence supporting the potential of
PZDHA as a novel therapeutic agent against human skin cancer.
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